



SDI Review Form 1.6

PART 1:

Journal Name:	<u>Ophthalmology Research: An international Journal</u>
Manuscript Number:	2013_OR_4933
Title of the Manuscript:	Postoperative Use of Cyclosporine, Prednisolone or a Cyclosporine/Prednisolone Combination to Treat Inflammation of the Conjunctiva Following Trabeculectomy in Rabbits
Type of the Article	Research paper

General guideline for Peer Review process is available in this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

- This form has total 7 parts. Kindly note that you should use all the parts of this review form.



SDI Review Form 1.6

PART 2: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	1-Please clarify in details the inclusion criteria 2-Please clarify the grades of fibrosis in details and its reference 3-Please clarify in methods section assessment of Factor VIII, and interleukin 6.	1- Thank you for your <u>suggestion</u>. We <u>have</u> added the next paragraph to Methods. "Only healthy animals and with no external ocular pathologies were included. All animals were <u>treated</u> previously with <u>anecto and endoparasiticid drug (also called endectocide) Ivermectin</u>, MerialBrasil, Campinas, São Paulo, Brazil) and <u>received</u> vitamin supplement <u>ation</u> (<u>ADE</u>, Pfizer Saúde Animal, São Paulo, Brazil), following <u>the university's vivarium rules</u>." 2-We <u>have added</u> <u>the required information</u> as follows "The anti-actin antibody revealed the degree of inflammatory fibrosis (fibroblasts marked by <u>this</u> antibody). This parameter was evaluated using <u>a</u> qualitative categorical <u>analysis and variables</u>. Numbers were assigned according to the staining intensity



SDI Review Form 1.6

		for the <u>actin</u> marker (1: minimum; 2: mild; 3: moderate; and 4: strong) in the histologic section for each 400x field. This analysis was carried out twice for each slide." We have published another paper using the same <u>method</u>. Faria N, Russ H, Rose P, Noronha L, Mello PA, Montiani-Ferreira F, Cronemberger S. "Conjunctival changes and inflammatory aspects in rabbits' conjunctivas induced by fixed combinations of prostaglandin analogues and timolol maleate". J Ophthalmic Inflammation and Infection 2013, 3:22 3. As suggested <u>by the reviewer</u>, we tried to clarify <u>the evaluation performed for the markers</u> factor VIII and IL-6. We added <u>the following</u> information: "<u>Anti-factor VIII is considered a marker for</u>
--	--	---



SDI Review Form 1.6

		vascular endothelial cells and therefore <u>for blood</u> vessel walls in the conjunctival tissue. The degree of neovascularization was determined by counting the number of <u>positively stained</u> blood vessels in each 400x field. Two counts were taken <u>on</u> each slide. The degree of inflammatory infiltrate was <u>analyzed</u> by counting the areas stained with anti-interleukin-6 antibody <u>on</u> histologic sections. This was also performed for each 400x field and carried out twice for each slide. <u>Interleukin-6 is a multifunctional cytokine expressed by a variety of cells after a multitude of stimuli, under complex regulatory control</u>
--	--	---



SDI Review Form 1.6

		mechanisms. The IL-6 response to injury is uniquely consistent and related to the magnitude of the insult. W L Biffl, E E Moore, F A Moore, and V M Peterson. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg. 1996 November; 224(5): 647–664. Interleukin-6 is critical for B-cell differentiation and maturation, immunoglobulin secretion, cytotoxic T-cell differentiation, acute-phase protein production, bone marrow progenitor stimulation, renal mesangial cell proliferation, and macrophage/monocyte
--	--	--



SDI Review Form 1.6

		<u>functions.</u> Kishimoto T: Interleukin-6: from basic science to medicine – 40 years in immunology. Annu Rev Immunol 2005, <u>23:1-21</u>
<u>Minor</u> REVISION comments	1- Some typographical errors and language errors should be corrected.	
<u>Optional/General</u> comments	Non	